

December 19th 2023

RE: Pharmacokinetics, pharmacodynamics, and safety of a new Leuprolide acetate 22.5 mg depot formulation, when given as palliative treatment to prostate cancer patients

Dear Ethics Committee/Competent Authority,

We are writing to inform you of the voluntary, business-related decision of the sponsor, Italfarmaco SpA (from now Italfarmaco), to close the clinical trial with EudraCT number 2006-005964-24 on the palliative treatment of **prostate cancer**.

The trial was prematurely ended because it never started.


This decision was made after Italfarmaco performed a careful and due diligent analysis of the current study status.

Italfarmaco remains committed to meeting the needs of patients with **prostate cancer** and to ongoing research in palliative treatments.

If you have any questions or require additional information, please contact Serena Franciosi at the following email: s.franciosi@italfarmacogroup.com.

Asking for your kind relevant actions.

Kindest regards,



Serena Franciosi,
Clinical Operations Lead
Italfarmaco S.p.A.